AIDS Therapies

HIV-1 Immunogen Induces Allo- And HIV Specific Immune Responses

Published in AIDS Weekly, July 2nd, 2001

The Immune Response Corporation (Nasdaq:IMNR) announced interim clinical results from an ongoing Phase II trial, indicating that treatment with Remune (HIV-1 Immunogen), an investigational product, appears to induce both allo- and HIV specific cell-mediated immune responses.

The data were presented at the Federation of Clinical Immunology Societies (FOCIS) first annual meeting in Boston, Massachusetts, May 4-7, 2001.

Research has shown that allo (allo-geneic) immune responses are directed to human leukocyte antigens (HLA) and are associated with development of both CD4⁺ T helper and CD8⁺ cytotoxic T-cell (CTL) immune responses. ...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2001-07-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry